Kid Risk, Inc., Orlando, Florida, USA.
Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Risk Anal. 2024 Feb;44(2):379-389. doi: 10.1111/risa.14159. Epub 2023 Jun 21.
In May 2016, the Global Polio Eradication Initiative (GPEI) coordinated the cessation of all use of type 2 oral poliovirus vaccine (OPV2), except for emergency outbreak response. Since then, paralytic polio cases caused by type 2 vaccine-derived polioviruses now exceed 3,000 cases reported by 39 countries. In 2022 (as of April 25, 2023), 20 countries reported detection of cases and nine other countries reported environmental surveillance detection, but no reported cases. Recent development of a genetically modified novel type 2 OPV (nOPV2) may help curb the generation of neurovirulent vaccine-derived strains; its use since 2021 under Emergency Use Listing is limited to outbreak response activities. Prior modeling studies showed that the expected trajectory for global type 2 viruses does not appear headed toward eradication, even with the best possible properties of nOPV2 assuming current outbreak response performance. Continued persistence of type 2 poliovirus transmission exposes the world to the risks of potentially high-consequence events such as the importation of virus into high-transmission areas of India or Bangladesh. Building on prior polio endgame modeling and assuming current national and GPEI outbreak response performance, we show no probability of successfully eradicating type 2 polioviruses in the near term regardless of vaccine choice. We also demonstrate the possible worst-case scenarios could result in rapid expansion of paralytic cases and preclude the goal of permanently ending all cases of poliomyelitis in the foreseeable future. Avoiding such catastrophic scenarios will depend on the development of strategies that raise population immunity to type 2 polioviruses.
2016 年 5 月,全球消灭脊灰行动(GPEI)协调停止使用所有 2 型口服脊髓灰质炎疫苗(OPV2),但用于紧急暴发应对除外。自那时以来,由 2 型疫苗衍生脊灰病毒引起的麻痹性脊灰病例已超过 39 个国家报告的 3000 多例。2022 年(截至 2023 年 4 月 25 日),20 个国家报告了病例检出,还有 9 个国家报告了环境监测检出,但无病例报告。最近开发的一种基因改造的新型 2 型口服脊髓灰质炎疫苗(nOPV2)可能有助于遏制产生神经毒力的疫苗衍生株;自 2021 年列入紧急使用清单以来,其使用仅限于暴发应对活动。先前的建模研究表明,即使假设 nOPV2 具有目前暴发应对性能的最佳特性,全球 2 型病毒的预期轨迹似乎也不会朝着根除的方向发展。2 型脊灰病毒持续传播使世界面临潜在高后果事件的风险,如病毒输入印度或孟加拉国的高传播地区。基于先前的脊灰终局建模,并假设目前的国家和 GPEI 暴发应对性能,无论选择哪种疫苗,我们都没有在近期成功根除 2 型脊灰病毒的可能性。我们还表明,最糟糕的情况可能导致麻痹病例迅速增加,并排除在可预见的未来永久结束所有脊髓灰质炎病例的目标。避免这种灾难性情况将取决于制定提高人群对 2 型脊灰病毒免疫力的战略。